Trials / Terminated
TerminatedNCT04362254
A Study to Test Long-term Treatment With Spesolimab in Patients With Fistulising Crohn's Disease Who Took Part in Previous Trials
An Open Label, Long Term Safety Trial of Spesolimab Treatment in Patients With Crohn's Disease Who Have Completed Previous Spesolimab Trials
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main objectives of this study are to evaluate the long-term safety of spesolimab in patients with perianal fistulising Crohn's disease who have completed treatment in parent trials and to evaluate the long-term efficacy of spesolimab in patients with perianal fistulising Crohn's disease, who have completed treatment in parent trials
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Spesolimab | Spesolimab |
Timeline
- Start date
- 2020-05-15
- Primary completion
- 2022-05-14
- Completion
- 2022-09-23
- First posted
- 2020-04-24
- Last updated
- 2025-02-24
- Results posted
- 2024-11-05
Locations
7 sites across 5 countries: Austria, Belgium, Germany, Netherlands, South Korea
Source: ClinicalTrials.gov record NCT04362254. Inclusion in this directory is not an endorsement.